Immunomodulators and Immunosuppressives in Vitiligo Treatment

Bishnoi, Anuradha; Parsad, Davinder

doi:10.1002/9781118937303.ch15

Cited by 3 publications

(12 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zinc 440 mg zinc orally once daily with topical steroid versus topical steroid monotherapy Bishnoi & Parsad, 2018 Case control study Response rate was higher in the combination group but the difference was not statistically significant.…”

Section: Minocyclinementioning

confidence: 93%

“…Cyclophosphamide is an alkylating agent (Bishnoi & Parsad, ). Due to the suppressive action of cyclophosphamide on lymphocytes and antibody production, it has been used widely in various autoimmune dermatoses and recently in vitiligo.…”

Section: Surgical Therapiesmentioning

confidence: 99%

“…It is known to have anti‐oxidant properties; therefore, it quenches the free radicals that cause melanocyte destruction in vitiligo. It can be used orally at a dose of 40 mg thrice daily or 60 mg twice a day (Bishnoi & Parsad, ). This drug, sometimes classified as a nutritional supplement, has been associated with a variety of side effects, including bleeding, thus familiarity with its adverse effects is desirable.…”

Section: Surgical Therapiesmentioning

confidence: 99%

“…Zinc has been used orally as zinc sulfate 440 mg per day in vitiligo patients (Bishnoi & Parsad, 2018).…”

Section: Zincmentioning

confidence: 99%

“…It is known to have anti-oxidant properties; therefore, it quenches the free radicals that cause melanocyte destruction in vitiligo. It can be used orally at a dose of 40 mg thrice daily or 60 mg twice a day (Bishnoi & Parsad, 2018).…”

Section: Ginko Bilobamentioning

confidence: 99%

See 4 more Smart Citations

Therapeutic options in vitiligo with special emphasis on immunomodulators: A comprehensive update with review of literature

Agarwal

Podder

Kassir

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Vitiligo is a relatively common disorder characterized by areas of depigmented skin. It may be associated with social stigma and adversely affects the quality of life. Although many treatment options are available, none is curable. The search continues for an effective therapeutic option. New targeted options include biologics and other immunomodulatory agents, with varying degrees of evidence. We have discussed briefly the therapeutic options with special emphasis on the newer immunomodulatory agents. We undertook a comprehensive English literature search across multiple databases such as PubMed, SCOPUS, EMBASE, MEDLINE, and Cochrane using keywords (alone and in combination) and MeSH items such as “vitiligo,” “treatment,” “recent,” and “immunomodulators” to obtain several relevant articles, priority being given to prospective randomized controlled trials. We scanned all the relevant articles and summarized them to obtain the latest information about the treatment of this condition to prepare the current article.

show abstract

Section: Minocyclinementioning

confidence: 93%

Section: Surgical Therapiesmentioning

confidence: 99%

Section: Surgical Therapiesmentioning

confidence: 99%

“…Zinc has been used orally as zinc sulfate 440 mg per day in vitiligo patients (Bishnoi & Parsad, 2018).…”

Section: Zincmentioning

confidence: 99%

Section: Ginko Bilobamentioning

confidence: 99%

See 3 more Smart Citations

Therapeutic options in vitiligo with special emphasis on immunomodulators: A comprehensive update with review of literature

Agarwal

Podder

Kassir

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

Vitiligo: What’s old, what’s new

et al. 2021

View full text Add to dashboard Cite

Vitiligo is an acquired pigmentary disorder afflicting 0.5-2% of the world population for both sexes and all races with a capricious and unpredictable course. It has a complex etiology and varies in its manifestation, progression and response to treatment. Even if the precise aetiology and pathobiology of the disease are complex and still debated, recent evidence supports that vitiligo is a T CD8+ cell-mediated autoimmune disease triggered by oxidative stress. To date no clinical, biological and histological criteria allow us to establish the prognosis with certainty. The choice of the best therapy for adult and childhood vitiligo is based on various factors, such as the patient’s age, psychological condition and expectations, distribution and extension of skin lesions, type of vitiligo (stable or not) and availability and cost of therapeutic options. Since vitiligo has a deep psychological impact on patients and their quality of life, treating the disease is very important. As dermatologists, we have important goals in the treatment of vitiligo patients: stabilization of the disease progression, repigmentation of the lesions and especially the persistence of the aforementioned repigmentation. Although several medical and surgical therapeutic options have been proposed, no definite cure has yet been developed and the long-term persistence of repigmentation is unpredictable. We review the different therapeutic options with particular attention on the recurrence rate.

show abstract

Macrophage Migration Inhibitory Factor in Vitiligo: Pathogenesis and Potential Therapeutic Aspects

Ibrahim

Nada

Ali

et al. 2021

AJBGMB

View full text Add to dashboard Cite

Vitiligo is an acquired skin disorder that is characterized by a gradual loss of skin pigmentation when melanocytes, the skin's pigment-producing cellsis lost. Pathogenicmechanisms are not well understood. Genetic, abnormal biochemical pathways, autoimmune, melanocyte adhesion deficits and nervous system imbalances are among the pathogenic triggers. Vitiligo lesions have also been shown to have macrophage infiltration.Macrophagemigration inhibitory factor (MIF) is a lymphokine that concentrates macrophages at inflammatory sites and is involved in cell-mediated immunity.MIF enhances chemotaxis and macrophage infiltration and upregulates inflammatory responses by inducing the expression of proinflammatory mediators such as TNF-α, nitric oxide and prostaglandin E2.Therapyfor vitiligo includes corticosteroids, immunomodulatory agents, vitamin D nalogues, antioxidants, phototherapy, laser and surgical therapy.However, no single treatment for vitiligo produces consistently good results and treatment response is variable. Narrow-band ultraviolet (NB-UVB, 311–313nm) phototherapy is viewed as backbone of treatment. Systemic therapies such as systemic corticosteroids and methotrexate were previously used to treat vitiligo which was assumed to be auto-immune nature.Pathogenic mechanisms, role of MIF and various treatment guidelines are discussed in this review

show abstract

Immunomodulators and Immunosuppressives in Vitiligo Treatment

Cited by 3 publications

References 35 publications

Therapeutic options in vitiligo with special emphasis on immunomodulators: A comprehensive update with review of literature

Therapeutic options in vitiligo with special emphasis on immunomodulators: A comprehensive update with review of literature

Vitiligo: What’s old, what’s new

Macrophage Migration Inhibitory Factor in Vitiligo: Pathogenesis and Potential Therapeutic Aspects

Contact Info

Product

Resources

About